Project: Tumor genome-based personalized anti-cancer mRNA vaccines off-the-shelf
| Acronym | ETHERNAL FRAME (Reference Number: 114238) |
| Duration | 01/09/2020 - 01/09/2022 |
| Project Topic | We will develop groundbreaking FraMix cancer vaccines that combine the expertise and unique technologies of Frame Therapeutics and eTheRNA Immunotherapies: (i) immunogenic frameshift neo-antigens, commonly expressed in tumors, enabling off-the-shelf vaccines, ii) a vaccination platform encompassing high quality anti-tumor T cell responses based on clinically validated TriMix mRNA and lipid nanoparticle delivery. The project delivers a vaccine for kidney cancer, ready for clinical development. |
| Network | Eurostars 2 |
| Call | Eurostars Cut–off 13 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | eTheRNA Immunotherapies NV | Partner | Belgium |
| 2 | Frame Pharmaceuticals BV | Coordinator | Netherlands |